2004
Hepatitis C incidence—a comparison between injection and noninjection drug users in New York City
Fuller C, Ompad D, Galea S, Wu Y, Koblin B, Vlahov D. Hepatitis C incidence—a comparison between injection and noninjection drug users in New York City. Journal Of Urban Health 2004, 81: 20-24. PMID: 15047780, PMCID: PMC3456148, DOI: 10.1093/jurban/jth084.Peer-Reviewed Original ResearchConceptsHepatitis C virusInjection drug usersNoninjection drug usersDrug usersHCV seropositiveRisk of HCVNew injection drug usersPerson-time analysisAnnual incidence rateHepatitis C incidenceAnnual incident rateHigh-risk practicesHCV incidenceHCV seroconvertersNon-IDUsHCV serologyHCV preventionC virusRisk factorsIncidence ratePrevention servicesOnset of injectionEarly preventionNew York CityRisk Survey
1997
Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland
Villano S, Vlahov D, Nelson K, Lyles C, Cohn S, Thomas D. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. Journal Of Clinical Microbiology 1997, 35: 3274-3277. PMID: 9399533, PMCID: PMC230161, DOI: 10.1128/jcm.35.12.3274-3277.1997.Peer-Reviewed Original ResearchConceptsInjection drug usersHCV infectionRisk factorsDrug usersDrug useDrug paraphernaliaHepatitis C virus infectionC virus infectionAnnual incidence rateActive drug useHigh-risk sexual practicesSharing of needlesHCV seroconversionHepatitis CAntibody testingOverall incidenceIncidence rateVirus infectionSerum samplesInfectionIncidenceHCVSexual practicesFrequent useParticipants
1996
Effect of Isoniazid Chemoprophylaxis on HIV-Related Mycobacterial Disease
Graham N, Galai N, Nelson K, Astemborski J, Bonds M, Rizzo R, Sheeley L, Vlahov D. Effect of Isoniazid Chemoprophylaxis on HIV-Related Mycobacterial Disease. JAMA Internal Medicine 1996, 156: 889-894. PMID: 8774208, DOI: 10.1001/archinte.1996.00440080089010.Peer-Reviewed Original ResearchConceptsM avium complexMycobacterial diseaseTuberculosis incidenceAvium complexCutaneous anergyIsoniazid chemoprophylaxisIsoniazid prophylaxisPreventive therapyRisk factorsIncidence rateCD4 lymphocyte cell countProspective observational cohort studyPPD-positive patientsTwice-weekly isoniazidWeeks of therapyObservational cohort studyLymphocyte cell countsMonths of diagnosisOverall incidence rateAnnual incidence ratePopulation-based dataStrong risk factorTuberculin-positive subjectsMycobacterium avium complexTuberculin-positive individuals